CD226 and neuroblastoma: Adequate expression of DNAM-1 enables NK cells to recognize and kill hematopoietic malignancies such as acute myeloid leukemia (AML) (45), multiple myeloma (MM) (39), and solid tumor cells such as melanoma (46) and NB (47), thus contributing to a favorable prognosis (45, 48).